Compare AbbVie Inc (ABBV) vs YieldMax AMZN Option Income Strategy ETF (AMZY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs YieldMax AMZN Option Income Strategy ETF — how do they compare? AbbVie Inc trades at $254.16 (market cap $449.91B), while YieldMax AMZN Option Income Strategy ETF trades at $10.68. The key difference: AbbVie Inc pays a 2.72% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | AMZY | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $261.07 | $16.61 |
52-Week Low | $184.85 | $10.26 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
AMZY trades at $10.74, up 0.51% today, with a bearish technical signal from moving averages. The ETF generates high weekly dividends but faces scrutiny over net asset value erosion. Recent news highlights consistent distribution announcements alongside analyst downgrades citing structural risks in its synthetic option strategy relative to Amazon's performance.
The outlook is cautious due to inevitable NAV erosion despite high yield, with total returns lagging Amazon. Risks include amplified downside exposure and unsustainable payouts. Investors prioritizing income may find appeal, but long-term capital appreciation appears constrained by the fund's design.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →
